Synektik

Synektik S.A. Announces Extraordinary General Meeting to Discuss Strategic Division

Synektik S.A., a leading Polish medical technology company, has scheduled an Extraordinary General Meeting (EGM) of Shareholders for March 19, 2026, at its headquarters in Warsaw. The meeting will address key corporate matters, including the proposed division of the company. The division involves transferring a portion of Synektik's assets to a newly established entity, SYN2BIO S.A., as part of a strategic restructuring plan.

The proposed division will see the transfer of a segment of Synektik's business, specifically related to the production of cardiomarkers and CBNC, to SYN2BIO S.A. This move is aimed at optimizing operations and focusing on core business areas. Shareholders of Synektik S.A. will receive shares in SYN2BIO S.A. in a 1:1 ratio, ensuring their proportional ownership in the new entity. The division will not affect Synektik's share capital, and the new shares will be listed on the Warsaw Stock Exchange.

The Supervisory Board of Synektik S.A. has positively endorsed the proposed resolutions, which will be presented for approval during the EGM. The company has also provided detailed procedural guidelines for shareholders to participate in the meeting and exercise their voting rights.

Relevance to Synektik S.A.: This development aligns with Synektik S.A.'s strategic focus on enhancing its operational efficiency and expanding its presence in the medical technology sector, particularly in the production of advanced diagnostic solutions.

Synektik S.A. Announces Planned Division and Asset Transfer to Syn2bio S.A.

Synektik S.A., a leading Polish medical technology company, has announced its intention to divide the company and transfer part of its assets to Syn2bio S.A., based in Warsaw. The division will involve the transfer of an organized part of Synektik's enterprise, specifically assets related to the "Kardioznacznik" and "CBNC" projects, to Syn2bio S.A. The process will be conducted in accordance with Article 529 § 1 point 4 of the Polish Commercial Companies Code (KSH).

The division plan, including all relevant documentation and an auditor's opinion, has been made publicly available on the websites of both companies and will remain accessible until the conclusion of the general meetings of both entities, where the division resolution will be adopted. The transfer will include both material and non-material assets, which are financially and organizationally distinct within Synektik's operations.

The division is part of Synektik's strategic efforts to streamline its operations and focus on its core business areas, including the production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare.

Relevance: This development aligns with Synektik S.A.'s business model, as it reflects the company's strategy to optimize its operations and focus on its key segments, including radiopharmaceuticals and advanced medical technologies.

Synektik S.A. Projects Growth in EBITDA and Expands Presence in New Markets

Synektik S.A., a leading Polish medical technology company, anticipates continued growth in normalized EBITDA and an increase in recurring revenues, according to Vice President Dariusz Korecki. The company plans to introduce its flagship da Vinci robotic surgical systems to the Baltic countries this year, marking a significant expansion into new markets. Additionally, Synektik expects the impact of its sales in Ukraine to become evident in the next financial year, signaling further international growth opportunities.

These developments align with Synektik's business strategy of expanding its footprint in the medical technology sector, particularly through the distribution of advanced robotic surgical systems and the provision of innovative healthcare solutions.

National Health Fund: A Key Element in Poland's Healthcare System

Dr. Piotr Bromber, a political scientist and economist, emphasizes the importance of the National Health Fund (NFZ) as a cornerstone of Poland's healthcare system in his latest book, "Narodowy Fundusz Zdrowia w systemie ochrony zdrowia. Pacjenci – Ekonomia – Polityka." With over 20 years of operation, NFZ is described as a valuable asset rather than a burden, playing a crucial role in financing healthcare services and addressing systemic challenges. Bromber highlights the need for strategic planning, improved patient satisfaction, and stable regulations to enhance NFZ's effectiveness.

While acknowledging criticisms, Bromber argues that NFZ's perceived shortcomings often stem from issues with healthcare providers rather than the fund itself. He advocates for a balanced approach that considers the perspectives of various stakeholders, including patients, policymakers, and healthcare providers. Recommendations include fostering trust, enhancing service quality, and refining the relationship between NFZ and the Ministry of Health to ensure long-term stability and efficiency.

Relevance to Synektik S.A.: The article underscores the importance of strategic healthcare financing and patient-centered approaches, aligning with Synektik S.A.'s focus on delivering advanced medical technologies and solutions that improve healthcare outcomes in Poland.

MedTech Solutions Signs Letter of Intent for Strategic Acquisition in Orthopedics and Surgery

MedTech Solutions has announced the signing of a letter of intent to acquire 100% of shares in a distribution company specializing in orthopedics and surgery. The target company, which operates in over 100 hospitals, reported a net profit of approximately PLN 1 million in 2025. The acquisition aims to strengthen MedTech Solutions' market position and lay the groundwork for further consolidation in the medical device sector.

The deal includes a term sheet expected to be finalized within 30 days, outlining key transaction parameters. The acquired company boasts a specialized four-person sales team and a portfolio of over 100 active distribution contracts with Polish hospitals, covering medical products in orthopedics and surgery. MedTech Solutions plans to integrate sales structures and leverage product synergies to optimize operational efficiency and enhance commercial effectiveness.

This acquisition marks the first step in building a larger distribution platform in the medical device segment. The process will involve due diligence and negotiation of transaction documentation, with completion contingent on meeting standard legal and formal requirements.

MedTech Solutions is listed on the NewConnect market.

Relevance to Synektik S.A.: The acquisition aligns with Synektik S.A.'s focus on distributing advanced medical technologies and solutions, highlighting the competitive landscape and opportunities for growth in the Polish healthcare market.

Challenges and Opportunities in Poland's Healthcare Pilot Programs

Poland's healthcare system is grappling with the prolonged implementation of pilot programs, initially designed as short-term projects to test and refine innovative solutions. Among the most notable is the pilot for Mental Health Centers (CZP), which has been extended multiple times since its inception in 2018 and is now set to run until the end of 2026. This program aims to provide comprehensive local support for individuals facing mental health crises, transitioning from institutional to community-based care. Despite its success in reaching hundreds of thousands of patients annually, scaling the model to cover the entire population remains a significant challenge.

Other pilot programs, such as trauma therapy, coordinated care for neurofibromatosis patients, and initiatives promoting physical activity, have also faced delays and extensions. Key barriers include legislative gaps, incomplete evaluations by the Agency for Health Technology Assessment and Tariff System (AOTMiT), and disruptions caused by the COVID-19 pandemic. Experts highlight the need for better project management and clearer end-goals to ensure these pilots transition into permanent, well-funded services.

Technological advancements, such as telemonitoring for heart failure patients and centralized e-registration systems, are also being tested, showcasing the potential for digital solutions to enhance healthcare delivery. However, scaling these innovations across hundreds of facilities remains a complex task.

The relevance of this article to Synektik S.A. lies in the company's role as a provider of advanced medical technologies and IT solutions, which could support the implementation and scaling of innovative healthcare models, including telemedicine and diagnostic systems.

Innovaris Expands Distribution of Versius Plus Surgical Robots in Poland

Innovaris, a subsidiary of Anmar Group, has announced plans to expand the distribution and installation of Versius Plus surgical robots in Poland. The advanced robotic system, developed by CMR Surgical, is recognized for its high level of digitalization, integration of artificial intelligence, and modular design, making it a future-oriented solution for minimally invasive surgeries. Currently, 11 Versius systems are operational in 10 Polish hospitals, with new installations planned in the coming months. The system's compact design and advanced features, such as fluorescence imaging and enhanced energy tools, have proven effective in complex procedures, including pediatric surgeries and reconstructive operations.

Innovaris emphasizes the importance of data-driven insights, enabling real-time monitoring and optimization during surgeries. The company also highlights the system's efficiency, with faster preparation times and reduced interoperative delays, making it a cost-effective choice for hospitals. Innovaris aims to focus on expanding its presence in general surgery, thoracic surgery, pediatrics, urology, and gynecology, while addressing the growing demand for alternatives to existing robotic systems.

Globally, Versius Plus has achieved over 250 installations and 40,000 procedures, with Poland emerging as a key market alongside countries like the UK, Italy, and India. Innovaris is committed to supporting hospitals in leveraging the system's capabilities to improve surgical outcomes and operational efficiency.

Relevance to Synektik S.A.: The article highlights the growing adoption of advanced surgical robotics in Poland, a market where Synektik S.A. plays a significant role as the exclusive distributor of the da Vinci robotic system. This development underscores the competitive landscape and the increasing demand for innovative medical technologies, aligning with Synektik's focus on cutting-edge healthcare solutions.

Synektik S.A. Announces Planned Division of Assets to Syn2bio S.A.

Synektik S.A., a leading Polish medical technology company, has announced its intention to divide its assets and transfer a portion to Syn2bio S.A., a Warsaw-based entity. The division will involve the transfer of an organized part of Synektik's enterprise, including material and immaterial assets related to the "Kardioznacznik" and "CBNC" projects. This process will be conducted in accordance with Article 529 § 1 point 4 of the Polish Commercial Companies Code (KSH).

The division plan, which outlines the terms and conditions of the transfer, was made publicly available on July 23, 2025, on the websites of both Synektik S.A. (Synektik Investor Center) and Syn2bio S.A. (Syn2bio). Supporting documents, including the auditor's opinion, are accessible online and at the headquarters of both companies until the conclusion of their respective general meetings, where the division will be formally approved.

The transfer aims to streamline Synektik's operations by focusing on its core business areas while enabling Syn2bio to develop the transferred projects further.

Relevance: This development aligns with Synektik S.A.'s strategic focus on innovation and specialization in medical technologies, particularly in the production of radiopharmaceuticals and advanced healthcare solutions.

Synektik Expands Distribution of da Vinci Surgical Robots to Ukraine

Synektik S.A., a leading Polish medical technology company, has announced the expansion of its exclusive distribution agreement with Intuitive Surgical to include Ukraine. The collaboration, which now spans Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia, and Ukraine, has also been extended until the end of 2031. This move aligns with Synektik's strategy to enhance the availability of advanced surgical technologies in Central and Eastern Europe.

Under the agreement, Synektik will provide the Ukrainian market with da Vinci robotic surgical systems, offering comprehensive support including sales, implementation, training, service infrastructure development, and regulatory and marketing assistance. By the end of 2025, Synektik had 83 da Vinci systems operating in Poland and a total of 121 across the region.

Synektik's CEO, Cezary Kozanecki, emphasized the company's commitment to expanding access to cutting-edge surgical solutions, stating that the new agreement provides a solid foundation for further growth in the region.

Relevance: This development highlights Synektik's strategic focus on expanding its footprint in the robotic surgery market, a key segment of its business model, and reinforces its position as a leader in distributing advanced medical technologies in Central and Eastern Europe.

Synektik Secures Contract with Świętokrzyskie Oncology Center for da Vinci Surgical System

Synektik S.A., a leading Polish medical technology company, has announced the signing of a contract with the Świętokrzyskie Oncology Center in Kielce for the delivery, installation, and commissioning of the da Vinci robotic surgical system. The deal is valued at PLN 18.3 million net. This advanced system will enhance the center's capabilities in performing minimally invasive surgeries with greater precision and control.

The agreement underscores Synektik's position as the exclusive distributor of Intuitive Surgical's da Vinci systems in Poland and highlights its commitment to providing cutting-edge medical technologies to healthcare institutions.

Breakthrough in Autonomous Robotic Surgery Achieved by MicroPort MedBot

Chinese medical robotics company MicroPort MedBot has announced a significant breakthrough in autonomous robotic surgery with the successful completion of an experimental procedure on animal models. Utilizing its advanced AI-driven surgical system, MicroGenius, the company demonstrated the ability to autonomously perform key stages of soft tissue surgery, including bile duct clamping and cutting, with an 88% success rate in a single attempt. The system also showcased real-time dynamic adjustments during the procedure, completing the entire surgery autonomously.

The MicroGenius model, powered by approximately 3 billion parameters, operates on a two-layer AI architecture. The higher layer, trained on 23,000 surgical video records, enables advanced understanding of the surgical field and procedure planning. The lower layer, trained on over 10,000 surgical samples, ensures precise robotic arm movements and stable operation. A novel training paradigm combining small-scale in vivo data with large-scale ex vivo data was employed, significantly reducing reliance on costly in vivo datasets. Additionally, the model demonstrated adaptability across various robotic systems, marking a milestone in the development of autonomous surgical algorithms.

This achievement represents a paradigm shift in robotic surgery, moving from rule-based automation to a holistic, AI-driven autonomous approach. MicroPort MedBot's innovation could pave the way for more precise, efficient, and accessible surgical solutions globally.

Relevance to Synektik S.A.: This development highlights advancements in robotic surgery, a field where Synektik S.A. is a key player as the exclusive distributor of the da Vinci surgical system in Poland. The progress in autonomous surgical systems underscores the importance of innovation in medical robotics, aligning with Synektik's focus on cutting-edge healthcare technologies.

Major Healthcare Reforms in Poland: Digitalization, New Medical Documentation Standards, and Changes to Sick Leave Policies

Poland is set to undergo significant healthcare reforms starting January 2026, with a focus on digitalization, improved patient services, and updated medical documentation standards. Key changes include the introduction of the Central e-Registration system, which will streamline appointment scheduling for patients through online platforms, mobile apps, and voice assistants. Initially available for cardiology and cancer prevention programs, the system will expand to cover all medical services by 2029. Healthcare facilities will face penalties for failing to integrate with the system.

Additionally, new regulations will mandate the use of electronic medical documentation (EDM) for emergency medical teams, including digital forms for rescue operations. This aims to enhance data security, improve patient care, and eliminate paper-based processes. Changes to medical documentation will also include standardized referral formats and digital storage requirements, improving the efficiency and accuracy of healthcare data exchange.

In occupational medicine, electronic medical certificates will be introduced, accessible via the Internet Patient Account (IKP). These certificates will include personalized health recommendations for employees, though employers will not have access to this data. Furthermore, significant updates to sick leave policies will allow nurses and physiotherapists to issue medical leave under specific conditions, while also enabling employees to work for one employer while on leave from another, provided it aligns with recovery goals.

Lastly, home rehabilitation services will be limited to 20% of ambulatory care time starting in 2026, with new billing rules for physiotherapy services to follow in April of the same year.

Relevance to Synektik S.A.: These reforms align with Synektik S.A.'s focus on healthcare IT solutions, such as its PACS imaging systems and Zbadani.pl platform, which could play a critical role in supporting the digital transformation of Poland's healthcare system.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the University Clinical Hospital No. 2 PUM in Szczecin. The contract, valued at a net amount of PLN 18,514,000, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-period service support. The project will be financed through the National Recovery and Resilience Plan and is set to be completed within 60 days of the agreement's signing. The system will come with a 36-month warranty from the final acceptance protocol date.

The agreement was finalized following a public procurement process and is considered a key milestone for Synektik S.A., as its value exceeds 5% of the Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leader in the Polish healthcare technology market.

Synektik S.A. Announces Adjustments to Resolutions from Annual General Meeting

On January 21, 2026, Synektik S.A., a leading Polish medical technology company, issued a correction to its previous report (No. 7/2026) regarding resolutions adopted during the Ordinary General Meeting (OGM) held on January 20, 2026. The correction addressed a clerical error in the number of valid votes cast for resolutions numbered 01/2026 to 10/2026, 12/2026, and 14/2026 to 17/2026. The correct figure is 4,759,046 valid votes, instead of the previously reported 4,759,946.

The OGM approved several key resolutions, including:

• Approval of the financial statements for FY2024, showing a net profit of PLN 91.9 million and consolidated net profit of PLN 102.9 million.
• Allocation of PLN 91.7 million for dividend distribution, equating to PLN 10.75 per share, with the dividend payout scheduled for February 2, 2026.
• Granting discharge to the Management Board and Supervisory Board members for their duties during FY2024.
• Approval of the Supervisory Board's report and the remuneration report for 2024.

The resolutions reflect Synektik's strong financial performance and commitment to shareholder value through dividend payouts. The company continues to solidify its position as a leader in medical technology, including the production of radiopharmaceuticals and distribution of advanced medical equipment such as the da Vinci surgical systems.

Relevance: This announcement highlights Synektik S.A.'s robust financial health and strategic focus on delivering value to shareholders, aligning with its business model of innovation in medical technology and healthcare solutions.

Key Shareholders of Synektik S.A. Announced Following General Meeting

On January 20, 2026, Synektik S.A., a leading Polish medical technology company, disclosed the list of shareholders holding at least 5% of total voting rights during the Ordinary General Meeting of Shareholders. The announcement highlights the significant stakeholders in the company, reflecting its ownership structure and strategic backing.

• MELHUS COMPANY LTD: 2,047,380 votes, representing 24.00% of total voting rights and 43.02% of votes at the meeting.
• KSIĄŻEK HOLDING SP. O.O.: 1,376,143 votes, representing 16.13% of total voting rights and 28.92% of votes at the meeting.
• Funds Managed by Nationale Nederlanden PTE SA: 764,923 votes, representing 8.97% of total voting rights and 16.07% of votes at the meeting.
• Government of Norway: 331,694 votes, representing 3.89% of total voting rights and 6.97% of votes at the meeting.

This announcement underscores the strong institutional and international interest in Synektik S.A., a company renowned for its leadership in medical technologies, including robotic surgery systems, radiopharmaceuticals, and IT solutions for healthcare.

Synektik S.A. Announces Dividend Payout for FY2024

On January 20, 2026, the Ordinary General Meeting of Shareholders of Synektik S.A. approved a resolution regarding the allocation of the company’s net profit for the fiscal year from October 1, 2024, to September 30, 2025. The net profit, amounting to PLN 91,938,937.50, will be distributed as follows:

• PLN 91,688,136.75 (99.7% of the net profit) will be allocated for dividend payments, equating to PLN 10.75 per share.
• PLN 250,800.75 will be transferred to the company’s reserve capital.

The shareholders also set the dividend record date as January 29, 2026, and the dividend payment date as February 2, 2026.

This announcement underscores Synektik S.A.'s strong financial performance and commitment to delivering value to its shareholders, aligning with its position as a leader in the medical technology and radioisotope production sectors.

Synektik S.A. Shareholders Approve Key Resolutions at Annual General Meeting

On January 20, 2026, Synektik S.A., a leading Polish medical technology company, held its Annual General Meeting (AGM) in Warsaw, where shareholders approved a series of critical resolutions. The meeting covered financial performance, dividend distribution, and governance matters, reflecting the company's robust operational and financial health.

Key resolutions included:

• Approval of the financial statements for the fiscal year ending September 30, 2025, which reported a net profit of PLN 91.9 million and total assets of PLN 345.7 million.
• Approval of the consolidated financial statements of the Synektik Group, showing a net profit of PLN 102.9 million and total assets of PLN 489.1 million.
• Allocation of 99.7% of the net profit (PLN 91.7 million) for dividend distribution, resulting in a dividend of PLN 10.75 per share, with the payout scheduled for February 2, 2026.
• Granting discharge to the Management Board and Supervisory Board members for their duties during the fiscal year.
• Positive opinion on the remuneration report for 2024, confirming compliance with corporate governance standards.

The AGM also confirmed the company's commitment to transparency and shareholder value by approving the Supervisory Board's report, which included evaluations of internal control systems and risk management processes.

Relevance: The resolutions align with Synektik S.A.'s business profile as a leader in medical technology and innovation, showcasing its financial stability, governance practices, and dedication to shareholder returns.

Synektik S.A. Publishes 2024 Executive and Supervisory Board Remuneration Report

On January 16, 2026, Synektik S.A., a leading Polish medical technology company, released its comprehensive report on the remuneration of its Management Board and Supervisory Board members for the fiscal year 2024. The report, prepared in compliance with the company’s remuneration policy and Polish public company regulations, outlines the total compensation received by board members, including fixed and variable components, as well as additional benefits such as medical care and vehicle allowances.

The report highlights that the remuneration structure is designed to align with Synektik’s long-term business strategy, ensuring stability, financial performance, and alignment with shareholder interests. For 2024, CEO Cezary Kozanecki received a total remuneration of PLN 3.09 million, with 65% comprising variable components tied to company performance. Vice President Dariusz Korecki earned PLN 1.85 million, with 63% of his compensation being performance-based. Supervisory Board members received fixed remuneration only, with no variable or additional benefits.

The report also includes an independent auditor’s assessment, confirming the completeness and compliance of the remuneration disclosures with applicable regulations. The auditor emphasized that the remuneration policy effectively supports Synektik’s strategic goals and ensures transparency in corporate governance.

Additionally, the report provides a five-year comparison of company performance, board remuneration, and average employee salaries, showcasing a 19% year-over-year increase in net profit for 2024, reaching PLN 91.94 million. This growth reflects the company’s robust financial health and its commitment to rewarding performance-driven leadership.

The full report and auditor’s opinion are available on Synektik’s official website.

Relevance: This article is relevant to Synektik S.A.’s business profile as it demonstrates the company’s commitment to aligning executive compensation with its strategic objectives, financial performance, and corporate governance standards, which are critical for its leadership in the medical technology sector.

Synektik S.A. Subsidiary Secures Major Contract for da Vinci Surgical System in Czech Republic

Synektik S.A., through its subsidiary SYNEKTIK Czech Republic, s.r.o., has signed a significant agreement with the Municipal Hospital in Ostrava, Czech Republic. The contract involves the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-based service support. The deal, valued at $3,044,856.01 net, was finalized following a public procurement process in compliance with Czech law.

The delivery of the system is expected within 180 days of the hospital's formal request, with a 24-month warranty period commencing upon the final acceptance of the system. The agreement is considered a key milestone for Synektik S.A., as its value exceeds 5% of the Group's equity, as reported in the latest financial statements. Revenue from this project will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract underscores Synektik S.A.'s leadership in distributing advanced medical technologies, particularly the da Vinci surgical system, and aligns with its strategic focus on expanding its presence in the medical equipment and IT solutions market.

Synektik S.A. Reports Strong Growth in Medical Equipment Orders in Q1 FY2025

Synektik S.A., a leading Polish medical technology company, has announced a significant increase in orders within its medical equipment, IT solutions, and services segment for the first quarter of the 2025 fiscal year. The Group secured orders worth approximately 148 million PLN, a notable rise compared to 114 million PLN in the same period of FY2024. Additionally, the backlog of orders awaiting execution as of December 31, 2025, reached 73.2 million PLN, a substantial increase from 4.3 million PLN on December 31, 2024. The value of active offers also grew to 165.9 million PLN, up from 123.4 million PLN in the previous year.

The company emphasized that these figures are preliminary estimates and may vary in the final results, which will be disclosed in the interim report for the period from October 1, 2025, to December 31, 2025.

Relevance: This growth highlights Synektik S.A.'s expanding role in the medical technology market, aligning with its business model of providing cutting-edge medical equipment, IT solutions, and services to healthcare institutions.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Provincial Specialist Hospital named after Blessed Father Jerzy Popiełuszko in Włocławek. The contract, valued at a net amount of PLN 13,069,826.74, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-period service support. The project will be financed through the National Recovery and Resilience Plan.

The delivery of the robotic system is scheduled to be completed within four weeks of the contract signing, with a warranty period of 60 months from the final acceptance protocol. The agreement was finalized following a public procurement process and is considered significant as its value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to the company's financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leader in the Polish healthcare technology market.

Synektik S.A. Secures Exclusive Distribution Agreement for Edison Histotripsy Systems

On January 8, 2026, Synektik S.A. announced the signing of an exclusive distribution agreement with HistoSonics Inc., a U.S.-based company specializing in advanced medical technologies. Under the agreement, Synektik will become the sole distributor of HistoSonics' Edison histotripsy systems in Poland, Czech Republic, Slovakia, Lithuania, Latvia, and Estonia. The agreement spans three years, with an option for automatic renewal for an additional two years.

The Edison system employs cutting-edge histotripsy technology, a non-invasive, non-thermal, and non-ionizing method for mechanically destroying both inoperable and resectable liver tumors. This innovative platform uses pulsed ultrasound energy to liquefy tumors at the subcellular level, with the remnants naturally absorbed by the body. The procedure is monitored in real-time using advanced imaging technologies, ensuring precision and effectiveness.

As part of the agreement, Synektik will oversee sales, servicing, consumables distribution, training, regulatory compliance, and marketing for the Edison systems in the designated regions. The partnership aligns with Synektik's strategic focus on expanding its portfolio of advanced therapeutic solutions, which is expected to significantly impact the company's financial performance.

Relevance: This agreement underscores Synektik's commitment to enhancing its position as a leader in advanced medical technologies, complementing its existing expertise in medical equipment distribution, radioisotopes production, and IT solutions for healthcare.

Synektik S.A. Announces Ordinary General Meeting of Shareholders for January 2026

Synektik S.A., a leading Polish medical technology company, has officially announced the convening of its Ordinary General Meeting of Shareholders, scheduled for January 20, 2026, at 12:00 PM. The meeting will take place at the company's headquarters in Warsaw, located at Józefa Piusa Dziekońskiego 3. The agenda includes key resolutions such as the approval of financial statements for the fiscal year ending September 30, 2025, the allocation of profits, and the distribution of dividends.

Among the significant items on the agenda are:

• Approval of the management board's report on the company's and the group's activities for FY2024.
• Approval of the standalone and consolidated financial statements for FY2024.
• Discussion and approval of the Supervisory Board's report and the remuneration report for 2024.
• Decisions on profit distribution, including a proposed dividend of PLN 10.75 per share.
• Granting discharge to members of the management and supervisory boards for their duties during FY2024.

Shareholders are encouraged to participate either in person or through authorized representatives. The company has provided detailed procedures for participation, including the submission of relevant documentation and the use of electronic communication for certain processes. The record date for participation is January 4, 2026, and shareholders must request a certificate of entitlement by January 5, 2026.

Further details, including the full agenda, draft resolutions, and procedural guidelines, are available on Synektik S.A.'s official website at https://synektik.com.pl/centrum-inwestora/walne-zgromadzenia/.

Relevance: This announcement is directly tied to Synektik S.A.'s business operations and governance, as it involves critical decisions on financial performance, profit allocation, and strategic oversight, which are essential for the company's stakeholders and future growth.

Synektik S.A. Proposes Dividend Payout of PLN 10.75 Per Share for FY2024

On December 22, 2025, the Management Board of Synektik S.A. announced its recommendation to the Ordinary General Meeting regarding the allocation of the company's net profit for the fiscal year 2024, which ended on September 30, 2025. The Board proposed allocating PLN 91,688,136.75, representing 99.7% of the company's net profit, for dividend distribution, equating to PLN 10.75 per share. The remaining profit will be added to the company's reserve capital.

The Board also recommended setting January 29, 2026, as the dividend record date and February 2, 2026, as the dividend payment date. The final decision on the profit allocation and dividend payout will be made by the Ordinary General Meeting.

Relevance: This announcement highlights Synektik S.A.'s strong financial performance and commitment to shareholder value, aligning with its position as a leading player in the medical technology and radioisotope production sectors.

Key Figures Shaping Poland's Healthcare System in 2023

As 2023 comes to a close, Poland's healthcare system reflects the contributions of numerous influential figures who have driven innovation, reform, and progress across various sectors. From advancements in medical technologies to systemic improvements, these leaders have left a significant mark on the industry.

Among the notable achievements, the integration of robotic surgery systems, such as the da Vinci platform, has revolutionized surgical precision and patient outcomes. Leaders like Cezary Kazanecki have played a pivotal role in expanding access to these technologies, with Synektik S.A. emerging as a key player in their distribution. The company has successfully supported hospitals in leveraging EU funds to adopt cutting-edge solutions, ensuring better healthcare delivery.

Additionally, figures like Piotr Suwalski have championed telechirurgical innovations, enabling remote robotic surgeries that enhance accessibility and efficiency. This aligns with Synektik's focus on advanced medical technologies and IT solutions, including imaging systems and platforms like Zbadani.pl.

Other leaders have emphasized the importance of coordinated care, data-driven strategies, and systemic reforms, which resonate with Synektik's commitment to improving healthcare infrastructure through IT solutions and long-term service agreements.

As Poland's healthcare system continues to evolve, the contributions of these individuals underscore the importance of collaboration, innovation, and strategic investments in medical technologies.

Relevance to Synektik S.A.: The article highlights advancements in robotic surgery and healthcare IT solutions, areas where Synektik S.A. plays a leading role as a distributor and innovator in Poland's medical technology landscape.

First Robotic Surgeries with da Vinci 5 System Performed in Poland at Medicover Hospital

Warsaw’s Medicover Hospital has successfully conducted Poland's first surgeries using the advanced da Vinci 5 robotic system. Among the procedures performed were radical pancreatic resections and tumor removals, led by Professor Marek Durlik and his surgical team. The da Vinci 5 system enhances surgical precision by providing high-resolution 3D imaging and advanced maneuverability tools, enabling minimally invasive operations with greater accuracy and control.

The introduction of this cutting-edge robotic technology marks a significant step in expanding Medicover Hospital's surgical capabilities. Since 2018, the hospital has been a leader in robotic surgeries in Poland, completing over 2,500 procedures. Anna Nipanicz, Director of Medicover Hospital, emphasized the transformative impact of robotic surgery on modern medicine, highlighting its role in improving treatment precision, patient safety, and overall care quality.

Medicover Hospital’s adoption of the da Vinci 5 system aligns with its commitment to technological advancement and innovation in healthcare.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci robotic systems in Poland, Synektik S.A. plays a pivotal role in advancing robotic surgery in the country, showcasing its leadership in providing cutting-edge medical technologies.

Surge in Robotic Surgery in Poland: 2024 Report Highlights Growth and Challenges

The Modern Healthcare Institute has released a comprehensive report detailing the rapid growth of robotic-assisted surgeries in Poland during 2024. The report reveals that 17,100 robotic surgeries were performed, marking a 70% increase compared to 2023. Among these, 88% utilized the da Vinci system, while Versius accounted for 12%, and the newly introduced Hugo system performed seven procedures. Urology dominated the field, with prostatectomies making up 61% of all robotic surgeries, followed by operations for kidney and bladder cancer. Gynaecological and colorectal surgeries also saw significant adoption of robotic systems.

Despite the growth, disparities in access remain evident, with the number of robotic surgeries per thousand cancer cases varying widely across regions. The report also highlights the financial implications, noting that the National Health Fund (NFZ) spent an incremental 82.1 million PLN on robotic surgery reimbursements compared to laparoscopic procedures. Efforts to reduce the cost gap between robotic and traditional surgeries are ongoing, with NFZ adjusting reimbursement rates.

Leading hospitals in robotic surgery include the Oncology Center in Bydgoszcz, UROVITA in Chorzów, and the Military Medical Institute in Warsaw. These institutions performed hundreds of procedures across various specialties, showcasing the versatility of robotic systems. Additionally, 19 new hospitals adopted robotic surgery in 2024, contributing to the growing network of 77 facilities utilizing robotic systems in Poland.

Robotic systems are also expanding into orthopedics and neurosurgery, with advancements in spine stabilization, brain surgeries, and joint replacements. The orthopedic sector has seen the introduction of new robotic systems, such as Velys and SkyWalker, further diversifying the market.

This report underscores the transformative impact of robotic surgery on healthcare in Poland, highlighting both its potential and challenges in achieving equitable access and cost efficiency.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci robotic surgical system in Poland, Synektik S.A. plays a pivotal role in the expansion of robotic surgery, aligning with its mission to deliver cutting-edge medical technologies and solutions to healthcare providers.

Synektik S.A. Completes Installation of da Vinci Surgical System for Private Medical Facility

Synektik S.A., a leading Polish medical technology company, has successfully completed the delivery, installation, and commissioning of the da Vinci robotic surgical system for a private medical facility. The agreement also includes personnel training and comprehensive service support during the 24-month warranty period. While the contract value remains confidential, the deal is significant as it exceeds 5% of the Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to Synektik's financial results for the fiscal year 2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This development aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci surgical system, and underscores its leadership in the Polish healthcare market.

Synektik Secures Multi-Million Contract with University Clinical Hospital in Poznań

Synektik S.A., a leading Polish medical technology company, has announced the signing of a significant agreement with the University Clinical Hospital in Poznań. The contract, valued at up to PLN 14.95 million net, ensures the ongoing supply of consumables for the da Vinci robotic surgical system, which is designed for minimally invasive procedures. This partnership underscores Synektik's commitment to supporting advanced medical technologies in healthcare institutions across Poland.

The agreement highlights Synektik's strategic focus on providing cutting-edge surgical solutions and long-term service support, aligning with its role as the exclusive distributor of the da Vinci robotic system in Poland.

Synektik S.A. Secures Multi-Million Contract with University Clinical Hospital in Poznań

Synektik S.A., a leading Polish medical technology company, has signed agreements with the University Clinical Hospital in Poznań for the supply of consumables for the da Vinci robotic surgical system. The contracts, awarded through an open tender process, have a total maximum net value of PLN 14,952,586.94 and will span a period of 36 months. The agreements adhere to standard terms for such contracts and are considered significant as their value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement. Revenue from these contracts is expected to positively impact the company’s financial results for fiscal years 2025-2028.

This development aligns with Synektik S.A.'s business profile as a key distributor of advanced medical technologies, including the da Vinci robotic surgical system, and underscores its role in supporting minimally invasive surgical solutions in Poland.

Polish Surgeons' Society and Medtronic Launch RasCo Program to Advance Robotic Surgery in Poland

The Polish Surgeons' Society (TChP) has partnered with Medtronic Poland to establish RasCo Poland, a comprehensive educational program aimed at advancing and standardizing robotic-assisted surgery (RAS) in Poland. The initiative includes a detailed training curriculum combining theoretical lessons and practical workshops at Medtronic's Warsaw training center. The program is designed to enhance the quality and safety of robotic surgeries, particularly in oncology and general surgery, with plans to expand into gynecology and other specialties. The collaboration also involves webinars, proctoring, and expert-led sessions to ensure surgeons gain proficiency in robotic techniques. This partnership marks a significant step toward professionalizing robotic surgery in Poland, improving patient outcomes, and increasing access to advanced surgical technologies.

Relevance to Synektik S.A.: The development of robotic surgery in Poland aligns with Synektik S.A.'s role as a leading distributor of the da Vinci robotic surgical system, highlighting the growing demand for robotic-assisted surgical solutions and training in the country.

Synektik S.A. Secures Key Contracts for Robotic Surgery Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of three significant contracts in December 2025, further solidifying its position in the healthcare sector. The agreements involve the delivery, installation, and servicing of advanced robotic surgery systems, including the da Vinci and Symani platforms, to prominent medical institutions in Poland.

• On December 3, 2025, Synektik signed a contract with the 5th Military Clinical Hospital in Kraków for the supply and installation of the Symani robotic system for micro- and supermicrosurgery. The deal, valued at PLN 10.88 million net, includes staff training and warranty services.
• On December 4, 2025, the company finalized a PLN 15.73 million net agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw for the delivery of a da Vinci robotic system, with a 36-month warranty period.
• On December 5, 2025, Synektik secured a two-year contract worth PLN 13.81 million net with the 4th Military Clinical Hospital in Wrocław for the supply of consumables for the da Vinci robotic system.

These contracts highlight Synektik's commitment to advancing minimally invasive surgical technologies and its leadership in the distribution and servicing of robotic systems in Poland.

Relevance to Synektik S.A.: These developments align with Synektik's core business model, which focuses on the distribution of cutting-edge medical technologies, including robotic surgery systems, and underscores its role as a key player in the Polish healthcare market.

Synektik S.A. Secures Major Agreement with 4th Military Clinical Hospital in Wrocław

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the 4th Military Clinical Hospital with Polyclinic SPZOZ in Wrocław. The contract, valued at a maximum net amount of PLN 13,806,915.40, pertains to the supply of consumable materials for the da Vinci robotic surgical system used by the hospital. The agreement spans a period of 24 months and adheres to standard contractual practices for such arrangements.

The deal is considered substantial by Synektik's management, as its value exceeds 5% of the Group's equity as reported in the latest financial statement. Revenues generated from this project are expected to positively impact the company's sales performance during the fiscal years 2025-2027.

Relevance: This agreement underscores Synektik's position as a key distributor of advanced medical technologies, particularly the da Vinci robotic surgical system, aligning with its strategic focus on medical equipment and consumables.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to MSWiA Medical Institute

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration (MSWiA) in Warsaw. The contract, valued at PLN 15,735,000.00 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgery system, along with necessary equipment, personnel training, and warranty-period service support. The system is scheduled for delivery by December 12, 2025, with a 36-month warranty starting from the final acceptance protocol signing.

The agreement was awarded through a public procurement process and is considered material due to its value exceeding 5% of Synektik Group's equity, as reported in the latest periodic financial statement. Revenue from this contract will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business of distributing advanced medical technologies, particularly the da Vinci robotic surgery system, reinforcing its position as a leader in the Polish healthcare technology market.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the 5th Military Clinical Hospital with Polyclinic SPZOZ in Kraków. The contract, valued at PLN 10,879,535.44 net, involves the delivery, installation, and commissioning of the Symani robotic surgery system for micro- and supermicrosurgery. Additionally, the agreement includes staff training and service support during a 36-month warranty period. The system is scheduled for delivery by December 10, 2025, following a public procurement process.

The deal is notable as its value represents nearly 5% of Synektik Group's equity, as reported in the latest financial statement. The revenue generated from this project will contribute to the company's financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement aligns with Synektik S.A.'s core business of providing advanced medical technologies, including robotic surgery systems, and reinforces its position as a key player in the healthcare technology sector.

Synektik S.A. Reports Robust Financial Growth and Strategic Developments in FY2024

Synektik S.A., a leading Polish medical technology company, has reported significant financial growth and strategic advancements for the fiscal year ending September 30, 2025. The company achieved total revenues of PLN 681.3 million, marking a 9% year-on-year increase. Key drivers included a 46% rise in sales of medical equipment and IT solutions, alongside a 12% growth in the radiofarmaceutical segment. EBITDA from continuing operations surged by 24% to PLN 177.1 million, with profitability improving to 26% from 22.9% in the previous year.

In the medical equipment segment, Synektik delivered 27 da Vinci robotic systems across Poland, Czechia, and Slovakia, bringing the total number of systems under its service to 113. The company also expanded recurring revenue streams, which grew by 60% year-on-year to PLN 311 million, driven by increased utilization of robotic systems and related services. Additionally, Synektik advanced its IT solutions, including the Zbadani.pl platform, which facilitates secure digital management of medical imaging data.

In the radiofarmaceutical segment, Synektik maintained steady growth, with revenues reaching PLN 50.5 million. The company also signed a licensing agreement with NUCLEO for the production and distribution of Glunektik in Latvia and Estonia, further strengthening its international presence.

Strategically, Synektik progressed its innovative cardiomarker project, conducting clinical trials in Europe and preparing for trials in the United States. The company also initiated a corporate restructuring to spin off its research and development activities into a new entity, Syn2bio S.A., to focus on pharmaceutical innovation and cardiomarker development.

Synektik's strong financial performance and strategic initiatives underscore its commitment to advancing medical technology and expanding its market presence.

Relevance: This article highlights Synektik S.A.'s core business areas, including medical equipment, IT solutions, and radiofarmaceuticals, while showcasing its strategic focus on innovation and international expansion, aligning with its business profile.

Synektik S.A. Announces Spin-Off of Syn2bio to Advance Cardiotracer Research and Commercialization

Synektik S.A., a leading Polish medical technology company, has announced plans to spin off its research division into a newly formed entity, Syn2bio. The company has submitted a prospectus to the Polish Financial Supervision Authority (KNF) in preparation for the issuance of Syn2bio's shares, which will be allocated to Synektik shareholders on a 1:1 basis. Both companies will be listed on the Warsaw Stock Exchange, with the division expected to be finalized by mid-2026.

Syn2bio will focus on advancing research and commercialization of Synektik's flagship cardiotracer project, an innovative radioisotope-based pharmaceutical designed for myocardial perfusion imaging and coronary artery disease diagnostics. The cardiotracer, protected by patents in key markets such as Europe and Japan, is undergoing the final phase of clinical trials, with registration processes planned for Europe and the United States upon successful completion. Synektik has already invested PLN 50 million to support Syn2bio's operations for 12-14 months post-prospectus approval.

The cardiotracer project holds significant global potential, particularly in the U.S., where approximately 7 million myocardial perfusion studies are conducted annually, and in Europe. Syn2bio aims to generate revenue through licensing agreements and direct production of the cardiotracer.

Synektik's remaining operations, including its production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare, will continue under the parent company.

Relevance: This development aligns with Synektik's strategic focus on innovation in radiopharmaceuticals and its commitment to expanding its global footprint in medical technology.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

On October 27, 2025, Synektik S.A., a leading Polish medical technology company, announced the signing of a significant contract with the Provincial Hospital in Bielsko-Biała. The agreement, valued at PLN 12,320,891.91 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with necessary equipment, personnel training, and warranty-period servicing. The contract was awarded through an open public tender, and the delivery is expected to be completed within 90 days of signing.

This development underscores Synektik S.A.'s position as the exclusive distributor of the da Vinci robotic surgical systems in Poland and highlights its commitment to advancing minimally invasive surgical technologies in the healthcare sector.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to Bielsko-Biała Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Provincial Hospital in Bielsko-Biała for the delivery, installation, and commissioning of the da Vinci robotic surgery system. The contract, valued at PLN 12,320,891.91 net, also includes staff training and comprehensive service support during the 60-month warranty period. The project will be financed through the National Recovery and Resilience Plan, with the system set to be delivered within 90 days of the agreement's signing.

The deal was finalized following a public procurement process and is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. The revenue from this project will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement underscores Synektik S.A.'s leadership in the distribution of advanced medical technologies, particularly the da Vinci robotic surgery system, aligning with its core business focus on innovative healthcare solutions and strengthening its market position in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of several significant contracts between October 20 and October 23, 2025, for the delivery and installation of advanced robotic surgery systems. These agreements highlight the company's growing presence in the healthcare sector and its commitment to providing cutting-edge medical solutions.

• October 20, 2025: Synektik signed a contract with the Provincial Hospital Complex in Elbląg for the supply, installation, and training related to the da Vinci robotic surgery system and the APOTECAchemo system for cytostatic drug preparation. The contract is valued at PLN 15,492,111.11 net.
• October 21, 2025: The company finalized an agreement with Szpitale Pomorskie Sp. z o.o. in Gdynia for the delivery and installation of the da Vinci robotic surgery system at the Specialist Hospital in Wejherowo. The contract is worth PLN 9,251,585.51 net.
• October 23, 2025: Synektik secured a deal with the Oncology Center in Poznań for the installation of the fifth-generation da Vinci robotic surgery system. The contract value is PLN 16,180,000.00 net.

Each contract includes comprehensive services such as equipment installation, personnel training, and warranty-period maintenance, ensuring seamless integration into the respective healthcare facilities.

Relevance to Synektik S.A. Profile: These contracts reinforce Synektik's position as a leader in robotic surgery systems and advanced medical technologies, aligning with its core business model of delivering innovative healthcare solutions.

Synektik S.A. Secures Major Contract for da Vinci 5 Surgical System with Wielkopolskie Centrum Onkologii

Synektik S.A., a leading Polish medical technology company, has announced the signing of a significant agreement with Wielkopolskie Centrum Onkologii in Poznań. The contract, valued at PLN 16,180,000.00 net, involves the delivery, installation, and commissioning of the fifth-generation da Vinci 5 robotic surgical system, along with necessary equipment, staff training, and warranty-period service support.

The agreement was finalized following a public procurement process and stipulates that the system will be delivered within 10 weeks of signing. The warranty period for the system extends to 36 months from the final acceptance protocol. The deal is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. Revenue from this project will contribute to the company’s financial results for FY2025, spanning October 2025 to September 2026.

This development underscores Synektik S.A.'s position as a leader in advanced medical technologies, particularly in robotic surgery, aligning with its business focus on distributing cutting-edge systems like the da Vinci platform and providing comprehensive service solutions.

Synektik S.A. Secures Contract for da Vinci Surgical System with Szpitale Pomorskie

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with Szpitale Pomorskie Sp. z o.o. for the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system. The system, designed for minimally invasive surgeries, will be installed at the Specialist Hospital F. Ceynowy in Wejherowo. The contract also includes additional equipment, staff training, and a 36-month warranty with service support. The deal, valued at PLN 9,251,585.51 net, was awarded through a public procurement process and is expected to be fulfilled within 60 days of signing.

The agreement is considered a key milestone for Synektik S.A., as its value represents 5% of the company’s equity, as reported in its latest financial statement. Revenue from this contract will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci surgical system, and reinforces its position as a leader in robotic surgery solutions in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery and Cytostatic Drug Preparation Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of significant contracts with the Provincial Integrated Hospital in Elbląg. The agreements, valued at a net total of PLN 15,492,111.11, involve the delivery, installation, and commissioning of the da Vinci robotic surgery system and the APOTECAchemo robotic system for cytostatic drug preparation. The contracts also include staff training and comprehensive service support during the warranty period.

The procurement was conducted through an open tender process and will be financed by the National Recovery and Resilience Plan. The da Vinci system is expected to be delivered within 12 weeks, while the APOTECA system will be delivered within 20 weeks. The warranty periods are set at 84 months for the da Vinci system and 60 months for the APOTECA system, starting from the signing of final acceptance protocols. The revenue from these contracts will contribute to Synektik's financial results for FY2025, spanning October 2025 to September 2026.

The contracts are deemed significant as their combined value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement, meeting the company's internal reporting standards.

Relevance: This development aligns with Synektik S.A.'s core business focus on providing advanced medical technologies, including robotic surgery systems, and reinforces its position as a key player in the Polish healthcare technology market.

Da Vinci 5: Revolutionizing Robotic Surgery with Advanced Innovations

The fifth-generation da Vinci surgical robot introduces 150 groundbreaking innovations, significantly enhancing precision, ergonomics, and operator control. Key advancements include a more powerful computational system, smoother arm movements, and a redesigned console offering high-resolution 3D imaging and personalized settings. A major breakthrough is the integration of Force Feedback technology, enabling surgeons to "feel" tissue resistance, improving safety and precision during procedures. These enhancements reduce surgery times by 15-20%, minimize complications, and lower healthcare costs by shortening patient recovery periods and hospital stays.

Da Vinci 5 is also future-ready, designed for integration with artificial intelligence, real-time data analysis, and augmented reality, paving the way for decision-support systems and remote surgical education. Despite increasing competition from Chinese robotic systems, the da Vinci platform maintains its edge with a robust clinical base, extensive training networks, and proven reliability, ensuring its continued leadership in robotic surgery.

This article is relevant to Synektik S.A. as the company is the exclusive distributor of da Vinci systems in Poland, aligning with its focus on delivering cutting-edge medical technologies and solutions to healthcare providers.

Polish Medical Supply System Shows Strengths but Requires Updates and Better Coordination

The Polish medical supply system for individually prescribed medical devices has been recognized as efficient, stable, and patient-friendly, but experts highlight the need for regular updates and improved coordination among public institutions. A report by POLMED and INNOWO titled “Medical Devices Issued on Prescription – The Polish System Compared to Neighboring Countries in the Context of Socio-Health Challenges” provides a comprehensive analysis of the system's financing and functionality.

In 2023, Poland issued nearly 413 million medical devices on prescription, ranging from incontinence pads and ostomy bags to wheelchairs, hearing aids, orthoses, and prosthetics. Public funding for these devices amounted to PLN 2.67 billion, averaging PLN 70.9 per capita—the lowest in Central Europe. Despite lower spending, Poland’s flexible financing model ensures strong health outcomes and faster access to innovative technologies compared to neighboring countries. This model allows patients to co-decide on product selection and adapt to market changes, making it resilient to economic shocks such as rising costs of raw materials and transportation.

However, challenges remain, including the aging population, outdated product lists, and fragmented funding sources (NFZ and PFRON). The report recommends regular updates to the product list, indexed funding limits, and streamlined coordination of funding sources. It also suggests involving national consultants, clinicians, patient groups, and industry representatives in the review process, with updates occurring at least every two years. Additionally, transparent procedures for introducing new product categories and adequate vacatio legis periods for regulatory changes are proposed.

Experts emphasize the importance of adapting the system to demographic shifts, technological advancements, and economic realities to ensure better access to modern medical devices and improved patient care.

Relevance to Synektik S.A.: The article highlights the importance of innovation and efficient distribution systems in the medical device sector, aligning with Synektik S.A.'s role as a leading distributor of advanced medical technologies and solutions in Poland.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Supplies

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw. The contract, valued at a maximum net amount of PLN 9,851,541.97, involves the supply of consumables for the da Vinci robotic surgical system used in minimally invasive procedures. The agreement, awarded through an open tender process, will span 12 months and adheres to standard contractual practices for such arrangements.

The deal is considered crucial by Synektik's management as its value exceeds 5% of the Group's equity reported in the latest financial statement, marking it as a material transaction under the company's internal reporting standards. Revenue from this contract is expected to positively impact Synektik's financial results for fiscal years 2025 and 2026.

Relevance: This agreement underscores Synektik's leadership in distributing advanced medical technologies, including the da Vinci surgical system, aligning with its core business model and strengthening its market position in Poland.

Synektik Introduces Revolutionary da Vinci 5 Surgical System to Poland

Synektik S.A., the exclusive distributor of Intuitive Surgical's da Vinci systems in Poland, has unveiled the fifth-generation da Vinci 5 surgical robot, marking a significant milestone in robotic-assisted surgery. This cutting-edge platform, equipped with over 150 technical innovations and enhanced computational power, enables surgeons to perform minimally invasive procedures with unprecedented precision, real-time data analysis, and seamless collaboration. The system integrates advanced features such as Force Feedback technology, immersive 3D visualization, and automated functionalities, ensuring greater autonomy and efficiency for surgeons.

Since 2018, over 33,000 procedures have been performed in Poland using da Vinci systems, with 73 robots currently operational across the country. Synektik has trained more than 300 operators and numerous surgical teams, solidifying Poland's position as a regional leader in robotic surgery. The da Vinci 5 system further enhances surgical workflows by integrating multiple technologies into a single platform, reducing the need for additional personnel and simplifying operations. Its applications span various specialties, including urology, gynecology, general surgery, and thoracic surgery, supporting over 200 types of procedures.

Synektik's comprehensive approach to implementing robotic surgery includes international certification training, technical support, and ongoing expertise, ensuring the successful adoption of this transformative technology. The introduction of da Vinci 5 underscores the company's commitment to advancing healthcare innovation and improving patient outcomes.

Relevance to Synektik S.A.: This article highlights Synektik's pivotal role in bringing advanced robotic surgical systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Shurui: A Revolutionary Surgical Robot Challenging Market Leaders

Beijing Surgerii Robotics Company Limited has unveiled Shurui, a groundbreaking surgical robot featuring a dual-continuum mechanism made of flexible nitinol rods, enabling multi-directional bending of instruments. The system supports multi-port, single-port, and hybrid procedures, making it the first of its kind to offer such versatility. Shurui has received CE certification for adult and pediatric procedures in urology, gynecology, general surgery, and thoracic surgery, positioning it as a competitive alternative to Intuitive Surgical's da Vinci systems.

Priced at approximately €2.28 million, Shurui is slightly cheaper than the da Vinci SinglePort (€2.77 million) but more expensive than other Chinese multi-port systems. The robot has already performed over 2,000 surgeries across 70 hospitals in China and 10 European centers, with plans for further expansion in Europe and potential approval in the U.S. Its inclusion in IRCAD's training program in Strasbourg highlights its growing prominence in the global surgical robotics market.

Shurui's innovative design includes manipulators inspired by snake anatomy, offering unmatched dexterity in confined spaces. The system's smaller port diameter (25–26 mm) addresses limitations of da Vinci SP in thoracic surgery, while its pediatric certification provides a competitive edge. Additionally, Shurui has demonstrated capabilities in remote surgeries, showcasing its reliability and precision in telemedicine applications.

Comparative studies have shown Shurui's performance to be on par with da Vinci SP in prostatectomy outcomes, while its advanced features, such as reduced port size and hybrid procedure support, make it a strong contender in the surgical robotics market.

Relevance to Synektik S.A.: The emergence of Shurui highlights increasing competition in the surgical robotics market, directly impacting Synektik S.A., the exclusive distributor of da Vinci systems in Poland. Understanding advancements like Shurui is crucial for Synektik to maintain its market position and adapt to evolving technologies.

Polish Parliament Approves Centralized Hospital Resource Monitoring System

The Polish Parliament has passed a law to establish the Central System for Monitoring Hospital Resources, known as the Provider Potential Registry (EPS). The system, developed by the Ministry of Health, will enable real-time tracking of hospital resources, including beds, medical staff, essential medical supplies, protective equipment, medical gases, and blood. The initiative aims to enhance pre-hospital care by reducing patient rejections at emergency departments and minimizing unnecessary patient transfers between hospitals. Additionally, the system will improve resource management during crises such as pandemics, natural disasters, or military conflicts. EPS will automate data collection directly from hospital IT systems, ensuring efficient reporting and enabling better decision-making in critical situations. The law also phases out COVID-19-specific data reporting requirements, which were introduced during the pandemic but never fully implemented.

Relevance to Synektik S.A.: The implementation of EPS aligns with Synektik S.A.'s focus on advanced IT solutions for healthcare, such as its PACS imaging systems and Zbadani.pl platform, highlighting potential opportunities for the company to contribute to the system's technological infrastructure.

Synektik Secures Medical Equipment Orders Worth 145 Million PLN in Q4 FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a significant increase in orders for medical equipment in the fourth quarter of the fiscal year 2024. The company secured contracts worth approximately 145 million PLN, marking a substantial growth compared to the 82.7 million PLN in orders obtained during the same period last year. This achievement underscores Synektik's expanding presence in the medical equipment market and its ability to meet growing demand for advanced healthcare solutions.

The relevance of this development lies in Synektik's core business model, which focuses on the distribution of cutting-edge medical equipment and IT solutions for healthcare, aligning with its strategic goals and market leadership in Poland.

Healthcare Spending in Poland Reaches 243.8 Billion PLN in 2023

According to data released by the Central Statistical Office (GUS) in the Monitor Polski, Poland's total healthcare spending in 2023 amounted to 243.8 billion PLN, marking a 24% increase compared to 2022's expenditure of 196.2 billion PLN. Public spending accounted for 189.1 billion PLN, with 162.4 billion PLN derived from mandatory health insurance systems and 26.8 billion PLN from government and local administration budgets. Private spending reached 54.7 billion PLN, including 38.6 billion PLN in direct household expenses and 16 billion PLN in other private expenditures.

This significant rise in healthcare investment highlights the growing demand for advanced medical technologies and services, aligning with Synektik S.A.'s focus on providing cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostic imaging.

Synektik S.A. Reports Significant Growth in Medical Equipment Orders for FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a substantial increase in orders within its medical equipment, IT solutions, and services segment. The company secured approximately 391 million PLN in orders for the 2024 financial year, compared to 360 million PLN in 2023. Notably, orders in Q4 2024 reached 145 million PLN, nearly doubling the 82.7 million PLN recorded in Q4 2023.

As of September 30, 2025, the backlog of orders awaiting fulfillment stood at 75.9 million PLN, a significant rise from 36.1 million PLN a year earlier. Additionally, the value of active offers at the end of the period increased to 198.7 million PLN, up from 141.5 million PLN in 2024. These figures are preliminary estimates and will be confirmed in the company’s interim financial report for the period ending September 30, 2025.

The growth in orders highlights Synektik’s strong market position and its ability to meet increasing demand for advanced medical technologies, including robotic surgical systems and diagnostic imaging solutions.

Relevance: This development underscores Synektik S.A.'s leadership in the medical technology sector, aligning with its business model of providing cutting-edge medical equipment and IT solutions to healthcare institutions.

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Izabela Laber-Napora, Head of the Rehabilitation Department, emphasized the importance of integrated care, noting that patients are transferred directly to rehabilitation within the same facility, ensuring faster recovery. Dr. Zbigniew J. Król, CEO of the hospital, described the investment in Velys as part of a broader strategy to position the hospital as a modern and patient-friendly healthcare center in the Dolina Baryczy region.

Milickie Centrum Medyczne is the third hospital in Poland to adopt the Velys system, following the Clinical Hospital of the Medical University of Łódź. The robotic system, developed by Johnson & Johnson, assists surgeons by analyzing patient anatomy in real-time and optimizing implant placement. Across Poland, over 20 hospitals utilize robotic systems for joint replacement surgeries, including Velys, Cori (Smith & Nephew), Rosa (Zimmer Biomet), Mako (Stryker), and OmniBotics. Some facilities have also expanded robotic applications to hip replacements.

Relevance to Synektik S.A.: This article highlights the growing adoption of robotic systems in Polish healthcare, a market where Synektik S.A. plays a key role as the exclusive distributor of the da Vinci surgical robot and a leader in advanced medical technologies.

Expansion of PET/CT Indications in Poland Set for January 2026

Starting January 2026, Poland will implement expanded indications for PET/CT imaging, enabling earlier detection and more effective treatment for a broader range of patients. The updated guidelines, outlined in a draft regulation by the President of the National Health Fund, include approximately 20 clinical scenarios eligible for public funding. This marks a significant milestone for nuclear medicine, as advocated by the Polish Society of Nuclear Medicine and other medical experts.

Key advancements include the introduction of PSMA-based radiopharmaceuticals for prostate cancer diagnostics, which outperform traditional fluorocholine methods by detecting cancer at lower PSA levels. Additionally, PET/CT imaging will now be available for neuroendocrine tumors, cervical and endometrial cancers, and non-cancerous conditions like parathyroid adenomas. These updates align Poland with European standards, enhancing diagnostic precision and therapeutic outcomes.

Experts emphasize the transformative impact of these changes, including improved patient prognoses, reduced healthcare costs, and better alignment with modern oncological practices. The expanded indications will also facilitate the use of cutting-edge radiopharmaceuticals and imaging techniques, addressing longstanding gaps in Poland's diagnostic capabilities.

Relevance to Synektik S.A.: As Poland's leading producer and supplier of radiopharmaceuticals, Synektik S.A. stands to benefit significantly from the increased demand for advanced PET/CT imaging solutions, reinforcing its position in the medical technology market.

Synektik Introduces Cutting-Edge Robotic Surgery Systems to Polish Market

Synektik S.A., a leading Polish medical technology company, has expanded its portfolio with the introduction of the latest generation da Vinci 5 robotic surgery system and the single-port da Vinci SP model. The company also launched the Ion endoluminal system for advanced pulmonary bronchoscopy diagnostics. These innovations mark a significant step in enhancing precision and efficiency in minimally invasive procedures.

The da Vinci 5 system, designed with machine learning capabilities and advanced AI algorithms, offers enhanced computational power and introduces haptic feedback for improved surgical precision. Priced at approximately 13 million PLN, it is 30% more expensive than its predecessor, the da Vinci Xi. The single-port da Vinci SP, priced at 12 million PLN, enables surgeries through a single incision, making it ideal for specialized procedures such as radical prostatectomy and head-and-neck surgeries.

Synektik also unveiled the Ion system, priced at 6 million PLN, which provides unparalleled accuracy in lung biopsies. With features like 180-degree maneuverability, fiber-optic construction, and advanced path-planning capabilities, Ion significantly reduces diagnostic time for lung cancer. While no Polish hospitals currently use Ion, its adoption is growing globally, with over 900 units operational in the U.S.

Synektik now manages 77 da Vinci robots in Poland, with projections of over 20,000 robotic surgeries in 2025. The company has trained more than 300 Polish surgeons and plans to open a training center in Warsaw, complementing its existing facility in Prague. Globally, Intuitive Surgical deployed 1,790 new robots in 2024, with a growing trend toward leasing and shared-use models. In total, 2.68 million surgeries were performed using da Vinci systems last year, underscoring their transformative impact on healthcare.

“2025 marks the 30th anniversary of robotic surgery development by Intuitive Surgical, a technology aimed at improving patient outcomes and expanding access to minimally invasive treatments,” said Cezary Kozanecki, founder and CEO of Synektik.

Relevance: This article highlights Synektik's strategic role in introducing advanced robotic systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Synektik S.A. Appoints Tomasz Wróbel as New Board Member to Drive Operational Transformation

Synektik S.A., a leading Polish medical technology company, has announced the appointment of Tomasz Wróbel as a Member of the Management Board, effective October 1, 2025. The decision was made by the Supervisory Board on September 22, 2025. Wróbel will serve as Chief Operating Officer, focusing on the standardization, integration, and digital transformation of internal processes.

According to official statements, Wróbel does not engage in any competitive activities or hold positions in competing entities. Additionally, he is not listed in the National Debtors Register. His professional background and qualifications are detailed in an accompanying document.

This appointment aligns with Synektik S.A.'s strategic focus on innovation and operational excellence, supporting its leadership in medical technologies, including robotic surgery systems and radiopharmaceuticals.

Synektik S.A. Secures Major Contract for Robotic Surgery System Installation in Zamość Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Independent Public Provincial Hospital named after Pope John Paul II in Zamość. The contract involves the delivery, installation, and commissioning of the da Vinci robotic surgery system, alongside adaptation and modernization of the hospital's operating block. Additionally, the agreement includes personnel training and service support during the 36-month warranty period.

The project, valued at PLN 19,131,798.99 net, was awarded through a public procurement process and will be financed by the National Recovery and Resilience Plan. The robotic system is expected to be delivered within eight months of the contract signing. The revenue generated from this project will contribute to Synektik's financial results for the fiscal year 2025-2026.

This contract is deemed significant by Synektik's management as its value exceeds 5% of the company's equity, as reported in its latest financial statement. The agreement aligns with Synektik's strategic focus on providing cutting-edge medical technologies and services to healthcare institutions.

Relevance: This development underscores Synektik's leadership in distributing advanced robotic surgery systems and highlights its commitment to expanding its footprint in Poland's healthcare sector.